MDGL
Madrigal Pharmaceuticals, Inc.$480.12+5.84 (+1.23%)Prev Close$474.28·MCap$10.77B·P/E—·Vol138.2K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
27
$89.52M
◆
Net Activity
Net Seller
$89.52M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Madrigal Pharmaceuticals, Inc. (MDGL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 27 insider sales totaling $89.52M. The most recent insider transaction was by Soergel David (officer: Chief Medical Officer), who sold $516.6K worth of shares on Jun 1, 2026. Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $10.77B.
MDGL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 1,042 | $495.74 | $516.6K | 10,033 |
| May 22, 2026 | Levy Richard S | director | Sell | 5,642 | $515.50 | $2.91M | 27,337 |
| May 18, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 844 | $515.90 | $435.4K | 11,075 |
| Mar 6, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,582 | $429.88 | $680.1K | 13,826 |
| Mar 6, 2026 | Huntsman Carole | officer: Chief Commercial Officer | Sell | 419 | $431.94 | $181.0K | 12,692 |
| Mar 6, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 360 | $431.94 | $155.5K | 12,138 |
| Mar 6, 2026 | Sibold William John | director, officer: President and CEO | Sell | 1,663 | $431.94 | $718.3K | 161,829 |
| Mar 6, 2026 | Taub Rebecca | director | Sell | 491 | $431.94 | $212.1K | 452,213 |
| Mar 2, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,183 | $427.21 | $505.4K | 9,257 |
| Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Sell | 910 | $493.78 | $449.3K | 0 |
| Jan 26, 2026 | Sibold William John | President and CEO | Sell | 1,577 | $492.42 | $776.5K | 0 |
| Jan 26, 2026 | Taub Rebecca | Director | Sell | 647 | $492.42 | $318.6K | 0 |
| Jan 20, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 692 | $497.36 | $344.2K | 8,910 |
| Jan 20, 2026 | Taub Rebecca | Director | Sell | 2,238 | $490.77 | $1.10M | 0 |
| Jan 13, 2026 | FRIEDMAN PAUL A | director | Sell | 24,440 | $522.59 | $12.77M | 210,204 |
| Jan 13, 2026 | Taub Rebecca | director | Sell | 17,130 | $522.76 | $8.95M | 473,039 |
| Jan 9, 2026 | FRIEDMAN PAUL A | Director | Sell | 280 | $551.24 | $154.3K | 0 |
| Jan 9, 2026 | Taub Rebecca | Director | Sell | 240 | $550.33 | $132.1K | 0 |
| Dec 10, 2025 | FRIEDMAN PAUL A | Director | Sell | 24,800 | $552.19 | $13.69M | 0 |
| Dec 3, 2025 | Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.38M | 0 |
| Nov 21, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.08M | 0 |
| Nov 5, 2025 | BATE KENNETH | Director | Sell | 16,575 | $484.30 | $8.03M | 0 |
| Aug 21, 2025 | Sibold William John | President and CEO | Sell | 7,616 | $400.18 | $3.05M | 0 |
| Aug 15, 2025 | BATE KENNETH | Director | Sell | 10,000 | $365.20 | $3.65M | 0 |
| Aug 11, 2025 | FRIEDMAN PAUL A | Director | Sell | 46,808 | $355.31 | $16.63M | 0 |
| Jul 18, 2025 | FRIEDMAN PAUL A | Director | Sell | 1,400 | $350.03 | $490.0K | 0 |
| Jul 16, 2025 | FRIEDMAN PAUL A | Director | Sell | 28,876 | $353.19 | $10.20M | 0 |
| Mar 10, 2025 | Dier Mardi | SVP and CFO | Sell | 258 | $323.04 | $83.3K | 0 |
| Mar 3, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597.8K | 0 |
| Feb 27, 2025 | BATE KENNETH | Director | Sell | 20,000 | $356.44 | $7.13M | 0 |
| Jan 27, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116.3K | 10,438 |
| Jan 27, 2025 | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531.0K | 54,303 |
| Jan 27, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217.2K | 456,662 |
| Jan 27, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34.5K | 4,955 |
| Jan 17, 2025 | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75.7K | 7,705 |
| Jan 17, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461.8K | 457,310 |
| Jan 17, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120.8K | 5,058 |
| Dec 5, 2024 | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1.14M | 11,520 |
| Nov 27, 2024 | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1.19M | 15,800 |
| Nov 22, 2024 | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218.0K | 10,785 |
| Nov 8, 2024 | Levy Richard S | Sell | 5,000 | $350.00 | $1.75M | 11,012-31% | |
| Nov 5, 2024 | Levy Richard S | Sell | 5,000 | $300.94 | $1.50M | 13,212-27% | |
| Sep 11, 2024 | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1.55M | 55,887 |
| Jun 18, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,900 | $280.00 | $532.0K | 5,500-26% |
| Jun 14, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 2,000 | $285.00 | $570.0K | 5,500-27% |
| May 23, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,036 | $231.34 | $239.7K | 5,500 |
| May 16, 2024 | CRAVES FRED B | Sell | 22,489 | $212.88 | $4.79M | 427,024 | |
| Apr 10, 2024 | FRIEDMAN PAUL A | Sell | 26,270 | $246.19 | $6.47M | 210,564 | |
| Apr 10, 2024 | Taub Rebecca | Pres., R&D, and CMO | Sell | 2,676 | $245.99 | $658.3K | 461,451 |
| Apr 5, 2024 | FRIEDMAN PAUL A | Director | Sell | 73,730 | $243.93 | $17.98M | 212,957-26% |
Showing 1–50 of 68
1 / 2
MDGL Insider Buying Activity
The following table shows recent insider purchases of Madrigal Pharmaceuticals, Inc. (MDGL) stock reported via SEC Form 4 filings.
No insider buying activity found for MDGL in the last 12 months.
MDGL Insider Selling Activity
The following table shows recent insider sales of Madrigal Pharmaceuticals, Inc. (MDGL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 1,042 | $495.74 | $516.6K | 10,033 |
| May 22, 2026 | Levy Richard S | director | Sell | 5,642 | $515.50 | $2.91M | 27,337 |
| May 18, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 844 | $515.90 | $435.4K | 11,075 |
| Mar 6, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,582 | $429.88 | $680.1K | 13,826 |
| Mar 6, 2026 | Huntsman Carole | officer: Chief Commercial Officer | Sell | 419 | $431.94 | $181.0K | 12,692 |
| Mar 6, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 360 | $431.94 | $155.5K | 12,138 |
| Mar 6, 2026 | Sibold William John | director, officer: President and CEO | Sell | 1,663 | $431.94 | $718.3K | 161,829 |
| Mar 6, 2026 | Taub Rebecca | director | Sell | 491 | $431.94 | $212.1K | 452,213 |
| Mar 2, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,183 | $427.21 | $505.4K | 9,257 |
| Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Sell | 910 | $493.78 | $449.3K | 0 |
| Jan 26, 2026 | Sibold William John | President and CEO | Sell | 1,577 | $492.42 | $776.5K | 0 |
| Jan 26, 2026 | Taub Rebecca | Director | Sell | 647 | $492.42 | $318.6K | 0 |
| Jan 20, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 692 | $497.36 | $344.2K | 8,910 |
| Jan 20, 2026 | Taub Rebecca | Director | Sell | 2,238 | $490.77 | $1.10M | 0 |
| Jan 13, 2026 | FRIEDMAN PAUL A | director | Sell | 24,440 | $522.59 | $12.77M | 210,204 |
| Jan 13, 2026 | Taub Rebecca | director | Sell | 17,130 | $522.76 | $8.95M | 473,039 |
| Jan 9, 2026 | FRIEDMAN PAUL A | Director | Sell | 280 | $551.24 | $154.3K | 0 |
| Jan 9, 2026 | Taub Rebecca | Director | Sell | 240 | $550.33 | $132.1K | 0 |
| Dec 10, 2025 | FRIEDMAN PAUL A | Director | Sell | 24,800 | $552.19 | $13.69M | 0 |
| Dec 3, 2025 | Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.38M | 0 |
| Nov 21, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.08M | 0 |
| Nov 5, 2025 | BATE KENNETH | Director | Sell | 16,575 | $484.30 | $8.03M | 0 |
| Aug 21, 2025 | Sibold William John | President and CEO | Sell | 7,616 | $400.18 | $3.05M | 0 |
| Aug 15, 2025 | BATE KENNETH | Director | Sell | 10,000 | $365.20 | $3.65M | 0 |
| Aug 11, 2025 | FRIEDMAN PAUL A | Director | Sell | 46,808 | $355.31 | $16.63M | 0 |
| Jul 18, 2025 | FRIEDMAN PAUL A | Director | Sell | 1,400 | $350.03 | $490.0K | 0 |
| Jul 16, 2025 | FRIEDMAN PAUL A | Director | Sell | 28,876 | $353.19 | $10.20M | 0 |
| Mar 10, 2025 | Dier Mardi | SVP and CFO | Sell | 258 | $323.04 | $83.3K | 0 |
| Mar 3, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597.8K | 0 |
| Feb 27, 2025 | BATE KENNETH | Director | Sell | 20,000 | $356.44 | $7.13M | 0 |
| Jan 27, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116.3K | 10,438 |
| Jan 27, 2025 | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531.0K | 54,303 |
| Jan 27, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217.2K | 456,662 |
| Jan 27, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34.5K | 4,955 |
| Jan 17, 2025 | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75.7K | 7,705 |
| Jan 17, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461.8K | 457,310 |
| Jan 17, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120.8K | 5,058 |
| Dec 5, 2024 | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1.14M | 11,520 |
| Nov 27, 2024 | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1.19M | 15,800 |
| Nov 22, 2024 | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218.0K | 10,785 |
| Nov 8, 2024 | Levy Richard S | Sell | 5,000 | $350.00 | $1.75M | 11,012-31% | |
| Nov 5, 2024 | Levy Richard S | Sell | 5,000 | $300.94 | $1.50M | 13,212-27% | |
| Sep 11, 2024 | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1.55M | 55,887 |
| Jun 18, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,900 | $280.00 | $532.0K | 5,500-26% |
| Jun 14, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 2,000 | $285.00 | $570.0K | 5,500-27% |
| May 23, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,036 | $231.34 | $239.7K | 5,500 |
| May 16, 2024 | CRAVES FRED B | Sell | 22,489 | $212.88 | $4.79M | 427,024 | |
| Apr 10, 2024 | FRIEDMAN PAUL A | Sell | 26,270 | $246.19 | $6.47M | 210,564 | |
| Apr 10, 2024 | Taub Rebecca | Pres., R&D, and CMO | Sell | 2,676 | $245.99 | $658.3K | 461,451 |
| Apr 5, 2024 | FRIEDMAN PAUL A | Director | Sell | 73,730 | $243.93 | $17.98M | 212,957-26% |
MDGL Insiders
Similar Stocks to MDGL
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B